Crossmark

2581 Vivacity MG phase 3 study: clinical trial of nipocalimab administered to adults with generalized myasthenia gravis

Crossref DOI link: https://doi.org/10.1136/bmjno-2023-ANZAN.39

Published Online: 2024-02-01

Published Print: 2023-08

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Ramchandren, Sindhu SH

Sanga, Panna PS

Wasef, Eriene EW

Sun, Hong HS
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct03772587 at ClinicalTrials.gov

Documents that mention this clinical trial

2581 Vivacity MG phase 3 study: clinical trial of nipocalimab administered to adults with generalized myasthenia gravis
https://doi.org/10.1136/bmjno-2023-anzan.39

AB0250 A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP CLINICAL TRIAL OF NIPOCALIMAB IN PARTICIPANTS WITH ACTIVE IDIOPATHIC INFLAMMATORY MYOPATHIES (SPIREA): STUDY DESIGN
https://doi.org/10.1136/annrheumdis-2024-eular.3020

nct04951622 at ClinicalTrials.gov

Documents that mention this clinical trial

Batoclimab as induction and maintenance therapy in patients with myasthenia gravis: rationale and study design of a phase 3 clinical trial
https://doi.org/10.1136/bmjno-2023-000536

21 Long-term safety and efficacy of nipocalimab in generalized myasthenia gravis: vivacity-MG3 open-label extension phase results
https://doi.org/10.1136/jnnp-2025-abn.21

2581 Vivacity MG phase 3 study: clinical trial of nipocalimab administered to adults with generalized myasthenia gravis
https://doi.org/10.1136/bmjno-2023-anzan.39